Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 8/2017

11.02.2017 | Original Article

Preclinical imaging characteristics and quantification of Platinum-195m SPECT

verfasst von: E. A. Aalbersberg, B. J. de Wit – van der Veen, O. Zwaagstra, K. Codée – van der Schilden, E. Vegt, Wouter V. Vogel

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Aims

In vivo biodistribution imaging of platinum-based compounds may allow better patient selection for treatment with chemo(radio)therapy. Radiolabeling with Platinum-195m (195mPt) allows SPECT imaging, without altering the chemical structure or biological activity of the compound. We have assessed the feasibility of 195mPt SPECT imaging in mice, with the aim to determine the image quality and accuracy of quantification for current preclinical imaging equipment.

Methods

Enriched (>96%) 194Pt was irradiated in the High Flux Reactor (HFR) in Petten, The Netherlands (NRG). A 0.05 M HCl 195mPt-solution with a specific activity of 33 MBq/mg was obtained. Image quality was assessed for the NanoSPECT/CT (Bioscan Inc., Washington DC, USA) and U-SPECT+/CT (MILabs BV, Utrecht, the Netherlands) scanners. A radioactivity-filled rod phantom (rod diameter 0.85-1.7 mm) filled with 1 MBq 195mPt was scanned with different acquisition durations (10-120 min). Four healthy mice were injected intravenously with 3-4 MBq 195mPt. Mouse images were acquired with the NanoSPECT for 120 min at 0, 2, 4, or 24 h after injection. Organs were delineated to quantify 195mPt concentrations. Immediately after scanning, the mice were sacrificed, and the platinum concentration was determined in organs using a gamma counter and graphite furnace – atomic absorption spectroscopy (GF-AAS) as reference standards.

Results

A 30-min acquisition of the phantom provided visually adequate image quality for both scanners. The smallest visible rods were 0.95 mm in diameter on the NanoSPECT and 0.85 mm in diameter on the U-SPECT+. The image quality in mice was visually adequate. Uptake was seen in the kidneys with excretion to the bladder, and in the liver, blood, and intestine. No uptake was seen in the brain. The Spearman correlation between SPECT and gamma counter was 0.92, between SPECT and GF-AAS it was 0.84, and between GF-AAS and gamma counter it was0.97 (all p < 0.0001).

Conclusion

Preclinical 195mPt SPECT is feasible with acceptable tracer doses and acquisition times, and provides good image quality and accurate signal quantification.
Literatur
1.
Zurück zum Zitat Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;13:698–9.CrossRef Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature. 1965;13:698–9.CrossRef
2.
Zurück zum Zitat O’Rourke N, Roqué i Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer (Review). Cochrane Database Syst Rev. 2010;16, CD002140. O’Rourke N, Roqué i Figuls M, Farré Bernadó N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer (Review). Cochrane Database Syst Rev. 2010;16, CD002140.
3.
Zurück zum Zitat Green JA, Kirwan JJ, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;3, CD002225. Green JA, Kirwan JJ, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;3, CD002225.
4.
Zurück zum Zitat Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9:13–21.CrossRefPubMed Lokich J, Anderson N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann Oncol. 1998;9:13–21.CrossRefPubMed
5.
Zurück zum Zitat Browman G, Hodson D, Mackenzie R, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001;23:579–89.CrossRefPubMed Browman G, Hodson D, Mackenzie R, Bestic N, Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck. 2001;23:579–89.CrossRefPubMed
6.
Zurück zum Zitat Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949–55.CrossRefPubMed Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949–55.CrossRefPubMed
7.
Zurück zum Zitat Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–30.CrossRefPubMed Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med. 1992;326:524–30.CrossRefPubMed
8.
Zurück zum Zitat Bosch ME, Sánchez AJR, Rojas FS, Ojeda CB. Analytical methodologies for the determination of cisplatin. J Pharm Biomed Anal. 2008;47:451–9.CrossRefPubMed Bosch ME, Sánchez AJR, Rojas FS, Ojeda CB. Analytical methodologies for the determination of cisplatin. J Pharm Biomed Anal. 2008;47:451–9.CrossRefPubMed
9.
Zurück zum Zitat Lange RC, Spencer RP, Harder HC. Synthesis and distribution of a radiolabeled antitumor agent: cis-diamminedichloroplatinum (II). J Nucl Med. 1971;13:328–30. Lange RC, Spencer RP, Harder HC. Synthesis and distribution of a radiolabeled antitumor agent: cis-diamminedichloroplatinum (II). J Nucl Med. 1971;13:328–30.
10.
Zurück zum Zitat Areberg J, Norrgren K, Mattsson È. Absorbed doses to patients from 191 Pt-, 193mPt- and 195mPt-cisplatin. Appl Radiat Isot. 1999;51:581–6.CrossRefPubMed Areberg J, Norrgren K, Mattsson È. Absorbed doses to patients from 191 Pt-, 193mPt- and 195mPt-cisplatin. Appl Radiat Isot. 1999;51:581–6.CrossRefPubMed
11.
Zurück zum Zitat Lange RC, Spencer RP, Harder HC. The antitumor agent cis-Pt(NH3)2Cl2: Distribution and dose calculations for 193mPt and 195mPt. J Nucl Med. 1972;14:191–5. Lange RC, Spencer RP, Harder HC. The antitumor agent cis-Pt(NH3)2Cl2: Distribution and dose calculations for 193mPt and 195mPt. J Nucl Med. 1972;14:191–5.
12.
Zurück zum Zitat Lagasse L, Pretorius G, Petrilli E, Ford LC, Hoeschele J, Kean C. The metabolism of cis-dichlorociammineplatinum (II): distribution, clearance, and toxicity. Am J Obstet Gynecol. 1981;139:791–8.CrossRefPubMed Lagasse L, Pretorius G, Petrilli E, Ford LC, Hoeschele J, Kean C. The metabolism of cis-dichlorociammineplatinum (II): distribution, clearance, and toxicity. Am J Obstet Gynecol. 1981;139:791–8.CrossRefPubMed
13.
Zurück zum Zitat Ewen C, Perera A, Hendry JH, McAuliffe CA, Sharma H, Fox BW. An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin. Cancer Chemother Pharmacol. 1988;22:241–5.CrossRefPubMed Ewen C, Perera A, Hendry JH, McAuliffe CA, Sharma H, Fox BW. An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin. Cancer Chemother Pharmacol. 1988;22:241–5.CrossRefPubMed
14.
Zurück zum Zitat Los G, Mutsaers P, Lenglet W, Baldew G, McVie J. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389–94.CrossRefPubMed Los G, Mutsaers P, Lenglet W, Baldew G, McVie J. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol. 1990;25:389–94.CrossRefPubMed
15.
Zurück zum Zitat Smith PS, Taylor DM. Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man. J Nucl Med. 1974;15:349–51.PubMed Smith PS, Taylor DM. Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammine platinum (II) in man. J Nucl Med. 1974;15:349–51.PubMed
16.
Zurück zum Zitat Iosilevsky G, Israel O, Frenkel A, et al. A practical SPECT technique for quantitation of drug delivery to human tumors and organ absorbed radiation dose. Semin Nucl Med. 1989;19:33–46.CrossRefPubMed Iosilevsky G, Israel O, Frenkel A, et al. A practical SPECT technique for quantitation of drug delivery to human tumors and organ absorbed radiation dose. Semin Nucl Med. 1989;19:33–46.CrossRefPubMed
17.
Zurück zum Zitat Shani J, Bertram J, Russell C, et al. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-Cisplatin in humans. Cancer Res. 1989;49:1877–81.PubMed Shani J, Bertram J, Russell C, et al. Noninvasive monitoring of drug biodistribution and metabolism: studies with intraarterial Pt-195m-Cisplatin in humans. Cancer Res. 1989;49:1877–81.PubMed
18.
Zurück zum Zitat Areberg J, Bjorkman S, Einarsson L, et al. Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin. Acta Oncol. 1999;38:221–8.CrossRefPubMed Areberg J, Bjorkman S, Einarsson L, et al. Gamma camera imaging of platinum in tumours and tissues of patients after administration of 191Pt-cisplatin. Acta Oncol. 1999;38:221–8.CrossRefPubMed
19.
Zurück zum Zitat Zamboni WC, Gervais AC, Egorin MJ, et al. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res. 2002;8:2992–9.PubMed Zamboni WC, Gervais AC, Egorin MJ, et al. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res. 2002;8:2992–9.PubMed
20.
Zurück zum Zitat Sathekge M, Wagener J, Smith SV, et al. Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Nuklearmedizin. 2013;52:222–7.CrossRefPubMed Sathekge M, Wagener J, Smith SV, et al. Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers. Nuklearmedizin. 2013;52:222–7.CrossRefPubMed
21.
Zurück zum Zitat Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54:83–9.CrossRefPubMed Bailey DL, Willowson KP. An evidence-based review of quantitative SPECT imaging and potential clinical applications. J Nucl Med. 2013;54:83–9.CrossRefPubMed
22.
Zurück zum Zitat van der Have F, Vanstenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med. 2009;50:599–605.CrossRefPubMed van der Have F, Vanstenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-high-resolution device for molecular small-animal imaging. J Nucl Med. 2009;50:599–605.CrossRefPubMed
Metadaten
Titel
Preclinical imaging characteristics and quantification of Platinum-195m SPECT
verfasst von
E. A. Aalbersberg
B. J. de Wit – van der Veen
O. Zwaagstra
K. Codée – van der Schilden
E. Vegt
Wouter V. Vogel
Publikationsdatum
11.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 8/2017
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-017-3643-2

Weitere Artikel der Ausgabe 8/2017

European Journal of Nuclear Medicine and Molecular Imaging 8/2017 Zur Ausgabe